The role of mammalian target of rapamycin inhibitor in virus infection of organ transplant recipients
10.3969/j.issn.1674-7445.2023.04.018
- VernacularTitle:哺乳动物雷帕霉素靶蛋白抑制剂在器官移植受者病毒感染中的作用
- Author:
Chunkai DU
1
;
Yichen ZHU
;
Jun LIN
Author Information
1. Department of Urology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China
- Publication Type:Research Article
- Keywords:
Mammalian target of rapamycin inhibitor;
Sirolimus (rapamycin);
Everolimus;
Cytomegalovirus;
SARS-CoV-2;
Influenza A virus;
BK virus;
Epstein-Barr virus
- From:
Organ Transplantation
2023;14(4):598-
- CountryChina
- Language:Chinese
-
Abstract:
At present, mammalian target of rapamycin (mTOR) inhibitors are commonly-used immunosuppressive drugs after organ transplantation, including sirolimus (rapamycin) and everolimus. mTOR inhibitors not only exert an immunosuppressive effect by inhibiting T cell proliferation, but also possess multiple potential functions, such as antiaging, anti-tumor and anti-virus infection, etc. Virus infection is one of the most common complications after organ transplantation. Current anti-viral treatments are limited and yield poor efficacy. In this article, the role of mTOR pathway in virus infection, the mechanism of common mTOR inhibitors and the role of mTOR inhibitors in different types of virus infections were reviewed, aiming to provide reference for clinical application and subsequent research of mTOR inhibitors in organ transplant recipients.
